Scleroderma disease. Systemic sclerosis
Conditions
Interventions
Intervention group: 15 patients with scleroderma will be included in the study, according to the diagnostic criteria of systemic sclerosis in 2013, the patients will be included in the study after eva
Sponsors
Espad Pharmed
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Suffering from Systemic sclerosis according to the 2013 criteria Age 70-18 Female sex According to the rheumatologist, the disease is in remission
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding BMI<17
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viscoelasticity. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: TEWAMETER probe.;Skin surface hydration. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Corneometer probe.;The maximum amount of mouth opening. Timepoint: At the beginning of the study, 1 and 3 months after injection. Method of measurement: Digital caliper.;The distance between the upper and lower front teeth. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Digital caliper.;Intercommissural distance. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Digital caliper.;Upper and lower lip thickness. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Digital caliper.;Dryness of skin. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Ask the patient.;Pain when opening the mouth. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Ask the patient.;Overall satisfaction with treatment. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Ask the patient.;The degree of skin elasticity improvement after treatment. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Ask the patient.;Transepidermal water loss. Timepoint: At the beginning of the study, 1 and 3 months after the injection. Method of measurement: Cutometer probe. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactvahide sadat lajevardi
Tehran University of Medical Sciences
Outcome results
None listed